Marc Frahm
Stock Analyst at TD Cowen
(0.20)
# 4,522
Out of 5,245 analysts
16
Total ratings
16.67%
Success rate
-19.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Marc Frahm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Maintains: Hold | $13 → $15 | $16.37 | -8.37% | 4 | Mar 23, 2026 | |
| NKTR Nektar Therapeutics | Initiates: Buy | n/a | $66.61 | - | 1 | Mar 17, 2026 | |
| INCY Incyte | Maintains: Buy | $101 → $128 | $97.16 | +31.74% | 4 | Jan 13, 2026 | |
| SANA Sana Biotechnology | Upgrades: Buy | n/a | $3.07 | - | 2 | Jan 8, 2025 | |
| CGEM Cullinan Therapeutics | Initiates: Outperform | n/a | $13.84 | - | 1 | Jun 15, 2023 | |
| XLO Xilio Therapeutics | Initiates: Outperform | n/a | $8.28 | - | 1 | Nov 16, 2021 | |
| NUVL Nuvalent | Initiates: Outperform | n/a | $102.12 | - | 1 | Aug 23, 2021 | |
| JANX Janux Therapeutics | Initiates: Outperform | n/a | $14.52 | - | 1 | Jul 6, 2021 | |
| BDTX Black Diamond Therapeutics | Initiates: Outperform | n/a | $2.28 | - | 1 | Feb 24, 2020 |
Theravance Biopharma
Mar 23, 2026
Maintains: Hold
Price Target: $13 → $15
Current: $16.37
Upside: -8.37%
Nektar Therapeutics
Mar 17, 2026
Initiates: Buy
Price Target: n/a
Current: $66.61
Upside: -
Incyte
Jan 13, 2026
Maintains: Buy
Price Target: $101 → $128
Current: $97.16
Upside: +31.74%
Sana Biotechnology
Jan 8, 2025
Upgrades: Buy
Price Target: n/a
Current: $3.07
Upside: -
Cullinan Therapeutics
Jun 15, 2023
Initiates: Outperform
Price Target: n/a
Current: $13.84
Upside: -
Xilio Therapeutics
Nov 16, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.28
Upside: -
Nuvalent
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $102.12
Upside: -
Janux Therapeutics
Jul 6, 2021
Initiates: Outperform
Price Target: n/a
Current: $14.52
Upside: -
Black Diamond Therapeutics
Feb 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.28
Upside: -